Arkolith/Insider Trading/PSTX/Form 4

Gergen Mark J

Executive Chairman, DirectorPoseida Therapeutics, Inc. (PSTX) · full profile →Form 4 · filed Dec 11, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$284K
Net Open-Market Flow
-$284K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 10, 2024Option exercise(M)30K$2.78$83K681K
Dec 10, 2024Sell(S)30K$9.46$284K651K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 10, 2024Option exercise(M)30K—$096K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-24-135466) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML